Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Measles has been eliminated in NSW for more than a decade; however outbreaks associated with international travel do occur. This EpiReview describes the epidemiology of measles in NSW from [2002][2003][2004][2005][2006][2007][2008][2009][2010][2011]. A total of 281 cases of measles were notified during the period, an average annual notification rate of 0.41 notifications per 100 000 population (range: 0.06-1.25). There were 139 hospitalisations recorded with a measles diagnosis in the 10-year reporting period, corresponding to a rate of 0.20 hospitalisations per 100 000 population. Of the 80 measles virus specimens genotyped, five genotypes were identified: D9 (38%), D8 (24%), D4 (16%), D5 (14%) with H1 identified less frequently (9%). No single genotype was associated with local transmission across successive years. To sustain good measles control, children should be vaccinated against measles on time through routine childhood immunisation, and all young adults who travel internationally should be vaccinated. Clinician awareness remains important in the early identification and control of measles to avoid further transmission during outbreaks and to enable the timely implementation of public health measures.Measles is an acute and highly contagious viral disease that is currently the most important cause of vaccinepreventable death globally. 1 Measles is rare in Australia with low rates of hospitalisation and death. 2 Measles is transmitted by airborne particles, droplets or fomites and humans are the only host of the measles virus. Common symptoms of measles include fever, rash, cough, coryza, conjunctivitis, diarrhoea and loss of appetite. Complications include ear infections, pneumonia, convulsions, croup, encephalitis and death. A milder illness is sometimes seen in vaccinated individuals, 3 and severe disease tends to occur in infants and malnourished persons. 1 Sub-acute sclerosing panencephalitis is a rare, delayed, fatal complication of measles virus infection.In Australia, measles-mumps-rubella (MMR) vaccines are scheduled as two doses for all children: the first at 12 months and the second at 4 years of age. 4 In 2013, the inclusion of measles-mumps-rubella-varicella vaccine (MMR-V) on the childhood immunisation schedule will bring forward the second measles dose to 18 months from 4 years. 5 In addition, documented immunity to measles has been a mandatory requirement for new health care workers in New South Wales (NSW) since 2007. In NSW, the percentage of children immunised with at least one dose of MMR at 2 years of age is 93.9%, 6 with some variation across local health districts (LHDs) and Aboriginal communities. 7 People at highest risk of measles infection include: infants aged less than 1 year (who are too young to be vaccinated); children aged 1-4 years who have received only a single dose of vaccine, especially if received late; and those born in the late 1960s to mid 1980s (who were neither infected with measles, nor vaccinated against it). 8Multiple lines of evidence suggest measl...
Measles has been eliminated in NSW for more than a decade; however outbreaks associated with international travel do occur. This EpiReview describes the epidemiology of measles in NSW from [2002][2003][2004][2005][2006][2007][2008][2009][2010][2011]. A total of 281 cases of measles were notified during the period, an average annual notification rate of 0.41 notifications per 100 000 population (range: 0.06-1.25). There were 139 hospitalisations recorded with a measles diagnosis in the 10-year reporting period, corresponding to a rate of 0.20 hospitalisations per 100 000 population. Of the 80 measles virus specimens genotyped, five genotypes were identified: D9 (38%), D8 (24%), D4 (16%), D5 (14%) with H1 identified less frequently (9%). No single genotype was associated with local transmission across successive years. To sustain good measles control, children should be vaccinated against measles on time through routine childhood immunisation, and all young adults who travel internationally should be vaccinated. Clinician awareness remains important in the early identification and control of measles to avoid further transmission during outbreaks and to enable the timely implementation of public health measures.Measles is an acute and highly contagious viral disease that is currently the most important cause of vaccinepreventable death globally. 1 Measles is rare in Australia with low rates of hospitalisation and death. 2 Measles is transmitted by airborne particles, droplets or fomites and humans are the only host of the measles virus. Common symptoms of measles include fever, rash, cough, coryza, conjunctivitis, diarrhoea and loss of appetite. Complications include ear infections, pneumonia, convulsions, croup, encephalitis and death. A milder illness is sometimes seen in vaccinated individuals, 3 and severe disease tends to occur in infants and malnourished persons. 1 Sub-acute sclerosing panencephalitis is a rare, delayed, fatal complication of measles virus infection.In Australia, measles-mumps-rubella (MMR) vaccines are scheduled as two doses for all children: the first at 12 months and the second at 4 years of age. 4 In 2013, the inclusion of measles-mumps-rubella-varicella vaccine (MMR-V) on the childhood immunisation schedule will bring forward the second measles dose to 18 months from 4 years. 5 In addition, documented immunity to measles has been a mandatory requirement for new health care workers in New South Wales (NSW) since 2007. In NSW, the percentage of children immunised with at least one dose of MMR at 2 years of age is 93.9%, 6 with some variation across local health districts (LHDs) and Aboriginal communities. 7 People at highest risk of measles infection include: infants aged less than 1 year (who are too young to be vaccinated); children aged 1-4 years who have received only a single dose of vaccine, especially if received late; and those born in the late 1960s to mid 1980s (who were neither infected with measles, nor vaccinated against it). 8Multiple lines of evidence suggest measl...
Skin disease due to viruses may be a primary infection of the epidermis or may arise secondary to systemic infection. Depending on the virus, the effects may be necrotic damage of the infected cells, proliferation and tumour formation or inflammation without major skin cell damage. The features of DNA and RNA virus infections and their skin manifestations are covered in this chapter.
In order to sustain the elimination of measles, timely reporting is important. The surveillance data in Korea from 2002–2009 was analyzed to determine the effect of sentinel laboratory surveillance, which was introduced in 2006, on the timeliness of measles reporting. The data were stratified by two surveillance periods, (A) before and (B) after 2006, and by cases confirmed clinically and cases confirmed by laboratory measures. During Period A, 113 suspected cases were reported, and 241 during Period B. There was no difference in the proportion of timely reporting among cases confirmed clinically between the two periods, whereas the proportion of cases confirmed by laboratory measures has increased. The mean notification interval in cases confirmed by laboratory measures was shortened from 39 to 16 days. In Korea, sentinel laboratory surveillance has enhanced earlier detection of suspected cases that had not been reported, improving the timeliness of measles surveillance. Adopting this new method may improve the timely collection of cases in other countries. J. Med. Virol. 86:322–328, 2014. © 2013 The Authors. Journal of Medical Virology Published by Wiley Periodicals, Inc.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.